Simonsson O

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.

Simonsson O, Bradley M, Black JC +3

Psychedelics align brain activity with context.

Stoliker D, Novelli L, Khajehnejad M +16

Politically Salient Events May Modulate Effects of Naturalistic Psychedelic Use on Support for Partisan Violence.

Simonsson O, Hendricks PS, Osika W +1

PreprintLSD

Child and maternal health outcomes following antenatal exposure to classic psychedelic substances: a systematic review

Sun S, Hanson C, Hendricks PS +9

Associations between psychedelic use and migraine history in Swedish twins.

Simonsson O, Sun S, Wesseldijk LW +3

Effects of psychedelic use on authoritarian attitudes revisited.

Simonsson O, Lyons T, Marks J +5

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial.

Hendricks PS, Lappan SN, Shelton RC +8

Advancing the Field of Psychedelic Epidemiology.

Simonsson O, Sun S, Hendricks PS +1

ArticleMDMA

Lifetime MDMA use and associations with meaning in life in the context of childhood trauma.

Olofsson M, Acar K, Simonsson O +5

Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use.

Carlisle NA, Simonsson O, MacCarthy S +5

The Promises and Pitfalls of Psychedelic Use Among Religious Leaders.

Simonsson O, Goldberg SB

Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.

Olofsson M, Osika W, Goldberg SB +6

Naturalistic psychedelic use and changes in depressive symptoms.

Simonsson O, Hendricks PS, Swords CM +2

Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.

Dourron HM, Bradley M, Simonsson O +4

Addressing blinding in classic psychedelic studies with innovative active placebos.

Aday JS, Simonsson O, Schindler EAD +1

Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.

Simonsson O, Goldberg SB, Osika W +5

Associations between psychedelic-related and meditation-related variables: A longitudinal study.

Simonsson O, Chaturvedi S, Hendricks PS +5

Lifetime classic psychedelic use and headaches: A cross-sectional study.

Bjurenfalk Z, Cosmo A, Simonsson O +1

PreprintPsilocybin

Psychedelics Align Brain Activity with Context

Stoliker D, Novelli L, Khajehnejad M +16

ArticleDMT

Can psychedelic use benefit meditation practice? Examining individual, psychedelic, and meditation-related factors.

Jiwani Z, Goldberg SB, Stroud J +7

On Minimizing Risk and Harm in the Use of Psychedelics.

Evans J, Aixalà M, Anderson BT +28

ArticleLSD

Rural-urban divide in risk perception of LSD: Implications for psychedelic-assisted therapy.

Bradley M, Grossman D, Simonsson O +2

ArticleMDMA

Psychedelic and MDMA-Related Adverse Effects-A Call for Action.

Simonsson O, Johnson MW, Hendricks PS

Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.

Simonsson O, Goldberg SB, Hendricks PS

PreprintDMT

Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors

Jiwani Z, Goldberg SB, Stroud J +7

Adolescent Psychedelic Use and Psychotic or Manic Symptoms.

Simonsson O, Mosing MA, Osika W +4

Development of a digital intervention for psychedelic preparation (DIPP).

McAlpine RG, Sacchet MD, Simonsson O +4

Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom.

Honk L, Stenfors CUD, Goldberg SB +6

Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.

Simonsson O, Hendricks PS, Stenfors CU +3

ArticleDMT

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Dourron HM, Nichols CD, Simonsson O +3

PreprintPsilocybin

Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach

McAlpine R, Krajnović K, Khan M +4

Psychedelic use and psychiatric risks.

Simonsson O, Goldberg SB, Chambers R +3

Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom.

Simonsson O, Osika W, Stenfors CUD +3

Alternative beliefs in psychedelic drug users.

Lebedev AV, Acar K, Horntvedt O +5

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.

Simonsson O, Carlbring P, Carhart-Harris R +5

Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.

Simonsson O, Stenfors CUD, Goldberg SB +2

Classic psychedelic use and current meditation practice.

Simonsson C, Chambers R, Hendricks PS +6

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.

Simonsson O, Hendricks PS, Chambers R +2

Classic psychedelics, health behavior, and physical health.

Simonsson O, Hendricks PS, Chambers R +2

ArticleAyahuasca

Preliminary evidence of links between ayahuasca use and the corpus callosum.

Simonsson O, Bouso JC, Kurth F +4

Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.

Mellner C, Dahlen M, Simonsson O

Prevalence and associations of classic psychedelic-related seizures in a population-based sample.

Simonsson O, Goldberg SB, Chambers R +3

Classic Psychedelics and Human-Animal Relations.

Pöllänen E, Osika W, Stenfors CUD +1

Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.

Simonsson O, Goldberg SB

Associations between lifetime classic psychedelic use and cardiometabolic diseases.

Simonsson O, Osika W, Carhart-Harris R +1

Europe PMC2021